Latest News

Newsletter August 2017

CEO comments I hope that you all have had a chance to enjoy some sunshine and warm days in July. Cyxone, in collaboration with our partners, has been working even during the month of July to ensure that the studies with T20K will go as planned, and to prepare financing for the Phase IIB studies […]

Read More

Newsletter July 2017

CEO’s comments Positive comments and questions about Cyxone, T20K and Rabeximod continue to flood in. I am grateful for all the interest, and felt that in this newsletter I would try to offer a little more background so that you could better grasp our reasoning. New safety data for T20K Development work on T20K is […]

Read More

Newsletter June 2017

CEO’s comments We have received many positive reactions and relevant questions since we announced our plans to acquire Phase II substance Rabeximod from OxyPharma. Naturally, a brief media release cannot provide comprehensive information about all the various aspects related to such an acquisition, so we will be looking to provide Cyxone shareholders with information in […]

Read More

MedUni Vienna technology wins Recognition Prize in the science2business awards

A joint project between MedUni Vienna and Freiburg University Hospital, using cyclotides as a treatment for multiple sclerosis, was awarded the Recognition Prize in the science2business awards. This development is an example of a successful transfer of innovation from research to the business world. Read the article published on Medical University of Vienna’s homepage

Read More

Newsletter April 2017

CEO’s comments I hope that you have all had a happy and pleasant Easter, even if the weather was rather patchy at times. In March and April, Cyxone, together with researchers in Vienna, Freiburg and our strategic partner Sourcia, processed the results of the T20K study with a view to developing a coherent plan to […]

Read More